logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Nov 2018
Arrowhead Pharmaceuticals Inc.
Initial clinical data from ongoing Phase 1/2 study of ARO-HBV
Chronic hepatitis B virus infection
Nov 2018
Arrowhead Pharmaceuticals Inc.
Initial data from Phase 1 clinical study of ARO-AAT
Rare genetic liver disease associated with alpha-1 antitrypsin deficiency
Q4 2018
Foamix Pharmaceuticals Ltd.
Top-line result from Phase 3 clinical study of FMX103 (FX2016-11)
Moderate-to-severe papulopustular rosacea
Q4 2018
Foamix Pharmaceuticals Ltd.
Top-line result from Phase 3 clinical study of FMX103 (FX2016-12)
Moderate-to-severe papulopustular rosacea
Q4 2018
Endocyte, Inc.
Submission of IND for EC17/CAR T-cell therapy
Osteosarcoma
Q4 2018
AVEO Pharmaceuticals, Inc.
Top line data readout from pivotal phase III trial comparing Tivozanib to Nexavar (sorafenib)
Refractory advanced renal cell carcinoma
Q4 2018
Arbutus Biopharma Corp.
Interim 6-week results from ongoing phase II study of ARB-1467 in combination with tenofovir (TDF), and pegylated interferon
Chronic Hepatitis B Virus (HBV)
Q4 2018
Sierra Oncology, Inc.
Preliminary data from monotherapy phase 1/2 trial of SRA737
Solid Tumors or Non-Hodgkin's Lymphoma
Q4 2018
Sierra Oncology, Inc.
Update from SRA737 phase 1/2 Low-Dose Gemcitabine combination trial into the cohort expansion phase II portion
Advanced Solid Tumors
Q4 2018
Tesaro Inc.
Submission of sNDA seeking label expansion for ZEJULA
Maintenance treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Q4 2018
Mirati Therapeutics, Inc.
IND filing of MRTX849
Non-small cell lung cancer
Q4 2018
SAGE Therapeutics, Inc.
Top-line data from placebo-controlled pivotal trial of SAGE-217
Postpartum Depression
Q4 2018
Kazia Therapeutics Limited
Safety and efficacy data from phase I study of Cantrixil
Ovarian cancer
01-Oct-2018 To 05-Oct-2018
Lexicon Pharmaceuticals Inc.
Phase 1b data for LX2761
Type 2 diabetes
01-Oct-2018 To 05-Oct-2018
Lexicon Pharmaceuticals Inc.
Phase 1a data for LX9211 (neuropathic pain candidate)
Healthy volunteers
Q4 2018
Progenics Pharmaceuticals Inc
Top-line data from phase II/III study of PyL (18F-DCFPyL) (OSPREY)
prostate cancer
Early Q4 2018
Acer Therapeutics Inc.
Submission of EDSIVO NDA
Ehlers-Danlos syndrome
Oct 2018
Epizyme, Inc.
Updated data from phase II study of Tazemetostat
Epithelioid sarcoma
Q4 2018
Fortress Biotech Inc.
Submission of IND filing for MB-102
Acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic syndrome (MDS)
Q4 2018
Unum Therapeutics Inc.
Initial data from phase I trial of ACTR087 in combination with SEA-BCMA (ATTCK-17-01)
Relapsed or refractory Multiple Myeloma
Q4 2018
Unum Therapeutics Inc.
Preliminary Data from Phase I Trial of ACTR707 in Combination with Rituximab (ATTCK-20-03)
CD20+ relapsed or refractory non-Hodgkin lymphoma
Q4 2018
Endo International plc
Top-line results from two phase III trials for collagenase clostridium histolyticum
Cellulite
Q4 2018
Unum Therapeutics Inc.
Updated data from cohort expansion phase of the ATTCK-20-2 Phase I Trial of ACTR087 in Combination with Rituximab
CD20+ relapsed or refractory non-Hodgkin lymphoma
Q4 2018
Puma Biotechnology Inc.
Additional data from phase II study of Neratinib (CONTROL)
Extended adjuvant treatment of HER2-positive early stage breast cancer
Q4 2018
Puma Biotechnology Inc.
Additional data from Phase II trial of Neratinib (SUMMIT)
Solid tumors with activating EGFR, HER2 or HER4 mutations